• About Us
  • News
  • Publications
  • Events
  • Careers
  • Contact
ProMabLogoProMabLogoProMabLogoProMabLogo
  • Login
  • 0 Items ($0.00)
    My Cart 1
  • Login
  • 0 Items ($0.00)
    My Cart 1
  • Top Sellers
    • CD19scFv-BEAM-CD28-CD3ZCD19scFv-BEAM-CD28-CD3ζ
    • CAR-T_Cell_MediumCAR-T Cell Medium
    • CD28-CD3_PM-T-Cell_Activation__Expansion_Beads_editCD28-CD3 Activation Beads
    • Cancer._Stem_PremiumCancer Stem Premium
    • P16_Antibody-v2P16 Antibody
  • Products
    • COVID19_8-04-2020COVID-19
    • primary-antibodyPrimary Antibody
      • Polyclonal Antibodies
      • Monoclonal Antibodies
    • Protein_IconFull-Length Protein
      • Recombinant Proteins
      • Natural Proteins
      • COVID-19 Research Products
    • CAR-T_iconCAR-T/CAR- NK
      • CAR-T cells
      • CAR-NK cells
      • T cell Activation Beads
      • Peripheral Blood Monocytes
    • Hempotological_products_IconHematological Products
      • Primary Cells
      • Non-Transduced T cells
      • Cell Media
      • Freezing Media
    • Icon_Product_mRNP_Lipid Nanoparticle_5_02_2022_finalmRNA-Lipid Nanoparticles
      • mRNA Products
      • LNP Products
    • stem-cell-iconCancer Stem Cells
      • Cancer Stem Cell Media
      • Hepatocellular Carcinoma (HCC)
      • Kidney Cancer
      • Ovarian Adenocarcinoma
      • Pancreatic Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
      • Lung Cancer Non-Small Cell (NSCLC)
      • Bladder Cancer
      • Breast Carcinoma
      • Colorectal Cancer
      • Glioblastoma
      • Head and Neck (H&N) Carcinoma
  • Services
    • v1-_Licensing_and_Distributing_CAR_Technology_7_22_2019_edit-1Licensing and Distributing CAR Technology
    • No_circles_-v2_Engineered_Cell_Lines-7_22_2019_finalCAR-T/CAR-NK Development
      • Custom CAR-T Cell Development
      • Custom CAR-NK Cell Development
      • Custom CAR-Macrophage Cell Development
      • Custom Gamma Delta T Cell Development
      • mRNA-LNP Gene Delivery
      • Lentivirus Production
      • Animal Research
      • Cancer Stem Cell Services
    • Cell_Based_Assay1_lastCell Based Assays
      • Flow Cytometry Services –
      • T Cell Specificity Assay
      • T Cell Activation & Proliferation Assay
      • Responsive T Cell Trafficking Assay
      • Cytokine Response Assay
      • Macrophage Polarization Assay
      • DC Migration Assay
    • Icon_ Services_mRNP_Lipid Nanoparticle_5_02_2022_finalmRNA-Lipid Nanoparticles
      • mRNA-LNP Gene Delivery
    • No_circles_-v3-Custom_Antibody_Engineering_7_22_2019_finalAntibody Engineering Services
      • Mouse Monoclonal Antibodies
      • Rabbit Monoclonal Antibodies
      • Human Monoclonal Antibodies
      • Recombinant Antibodies
      • Bispecific Antibodies
      • Antibody Humanization
      • Rabbit Polyclonal Antibodies
      • Hybridoma Sequencing
      • Antibody Production
    • No_circles_-v4-Protein_Expression_Services_7_22_2019_finalProtein Expression Services
      • E.coli Expression
      • Baculovirus Expression
      • Mammalian Expression
      • Stable Cell Line Development
      • Peptide Synthesis
      • Gene Synthesis Services
  • Protocols & Troubleshooting
    • Protocols
    • Technology
    • Troubleshooting
    • FAQ
Products & Custom Orders for 2019 Novel Coronavirus Research
February 4, 2020
Quick Facts
ProMab Presents Promising Results in Humanized CD19 CAR-T Cells Trial
July 28, 2020

Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA

 

BERKELEY, Calif. & RICHMOND, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies. Caribou intends to utilize this scFv in the development of its CB-011 program, an allogeneic CAR-T therapy targeting BCMA-positive tumors including multiple myeloma.

“We are excited for the opportunity to have access to this highly advanced, humanized molecule and believe it will significantly advance our promising CB-011 CAR-T program,” said Steven Kanner, PhD, Chief Scientific Officer of Caribou.

“We anticipate that our humanized BCMA scFv will aid greatly in Caribou’s efforts to further its allogeneic CAR-T program, and hope our technology continues to improve the field of preclinical and clinical stage immunotherapy research by providing broad choices of validated antibodies, “ said John Wu, MD, Chief Executive Officer of ProMab.

Under the terms of the agreement, ProMab received an upfront payment and is eligible for royalties on net sales of licensed products containing the BCMA scFv.

About Caribou Biosciences, Inc.
Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies, other gene-edited cell therapies, and engineered gut microbes. Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. Interested companies may contact Caribou at licensing@cariboubio.com. For more information about Caribou, visit www.cariboubio.com and follow the Company @CaribouBio. “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

About ProMab Biotechnologies, Inc.
ProMab Biotechnologies focuses on developing and commercializing mouse, rabbit, and human monoclonal antibodies as well as chimeric antigen receptor-T Cell (CAR-T) products. ProMab’s CAR-T platform covers both hematological and solid cancers with intensive in vitro and in vivo pre-clinical validation designed for safer and better treatment. As a CRO in the immunology field for 19 years, ProMab offers standard laboratory procedures and animal studies for antibody discovery through the integration of the newest techniques in antibody library construction, next generation sequencing, unique humanization modeling, high-throughput screening, and artificial intelligence analysis systems. ProMab aims to out-license antibodies validated in CAR-T therapy in the preclinical stage or to bring CAR-T technologies to the early stage market of clinical study. ProMab has partnered with top biotechnology startups, medical institutions, and pharmaceutical companies to advance the development of cell therapies as well as bispecific antibodies targeting multiple cancers. For more information, visit www.promab.com.

Share

Sign up for news & promotions:

Products

  • Antibodies
  • Proteins
  • CAR T/NK Cells
  • Cell Lines
  • Cell Culture

Services

  • CAR-T/CAR-NK Development
  • Custom Antibodies
  • Synthesis and Expression
  • Clinical Research

Resources

  • Protocols
  • Technology
  • Troubleshooting
  • FAQ

Promab Biotechnologies

  • Promotions
  • About
  • News
  • Publications
  • Careers
  • Contact Us
Copyright © ProMab 2022 All Rights Reserved ProMab Biotechnologies, Inc. | 2600 Hilltop Drive, Building B, Suite C320, Richmond, CA 94806 USA | Email: info@promab.com